Tectonic Therapeutic (TECX) Stock Overview
A biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TECX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Tectonic Therapeutic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.06 |
| 52 Week High | US$36.03 |
| 52 Week Low | US$14.39 |
| Beta | 0 |
| 1 Month Change | -4.78% |
| 3 Month Change | 29.04% |
| 1 Year Change | 33.64% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 70.84% |
Recent News & Updates
Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2
Apr 16Companies Like Tectonic Therapeutic (NASDAQ:TECX) Are In A Position To Invest In Growth
Nov 10
Recent updates
Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2
Apr 16Companies Like Tectonic Therapeutic (NASDAQ:TECX) Are In A Position To Invest In Growth
Nov 10We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth
May 20Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF
Apr 23Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Feb 05Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside
Jan 30We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth
Jan 10Tectonic Therapeutic: Waiting For A Pullback
Dec 30Tectonic Therapeutic: Interesting CV Disease Drug Developer
Oct 20Here's Why We're Not Too Worried About Tectonic Therapeutic's (NASDAQ:TECX) Cash Burn Situation
Sep 22Tectonic Therapeutic: Analyzing Its Post-Merger Valuation And Prospects
Aug 05Shareholder Returns
| TECX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.8% | -2.4% | 0.8% |
| 1Y | 33.6% | 27.4% | 27.8% |
Return vs Industry: TECX exceeded the US Biotechs industry which returned 27.4% over the past year.
Return vs Market: TECX exceeded the US Market which returned 27.8% over the past year.
Price Volatility
| TECX volatility | |
|---|---|
| TECX Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TECX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TECX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 60 | Alise Reicin | tectonictx.com |
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin.
Tectonic Therapeutic, Inc. Fundamentals Summary
| TECX fundamental statistics | |
|---|---|
| Market cap | US$547.74m |
| Earnings (TTM) | -US$74.15m |
| Revenue (TTM) | n/a |
Is TECX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TECX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$74.15m |
| Earnings | -US$74.15m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TECX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 07:22 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tectonic Therapeutic, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Risinger | Leerink Partners LLC |
| Cory Jubinville | LifeSci Capital, LLC |
| Uy Ear | Mizuho Securities USA LLC |